1235 related articles for article (PubMed ID: 20129531)
1. Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial.
Patel MR; Worthley SG; Stebbins A; Dill T; Rademakers FE; Valeti US; Barsness GW; Van de Werf F; Hamm CW; Armstrong PW; Granger CB; Kim RJ
JACC Cardiovasc Imaging; 2010 Jan; 3(1):52-60. PubMed ID: 20129531
[TBL] [Abstract][Full Text] [Related]
2. Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy.
Ezekowitz JA; Armstrong PW; Granger CB; Theroux P; Stebbins A; Kim RJ; Patel MR
Am Heart J; 2010 Aug; 160(2):272-8. PubMed ID: 20691832
[TBL] [Abstract][Full Text] [Related]
3. Aborted myocardial infarction after primary percutaneous coronary intervention: magnetic resonance imaging insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.
Patel MR; Westerhout CM; Granger CB; Brener SJ; Fu Y; Siha H; Kim RJ; Armstrong PW
Am Heart J; 2013 Feb; 165(2):226-33. PubMed ID: 23351826
[TBL] [Abstract][Full Text] [Related]
4. Effect of bivalirudin compared with unfractionated heparin plus abciximab on infarct size and myocardial recovery after primary percutaneous coronary intervention: the horizons-AMI CMRI substudy.
Wöhrle J; Merkle N; Kunze M; Cristea E; Mehran R; Rottbauer W; Stone GW
Catheter Cardiovasc Interv; 2012 Jun; 79(7):1083-9. PubMed ID: 22162175
[TBL] [Abstract][Full Text] [Related]
5. Myocardial infarct size reduction with pexelizumab: the role of chance is patently clear.
Gibson CM; Pride YB
JACC Cardiovasc Imaging; 2010 Jan; 3(1):61-3. PubMed ID: 20129532
[No Abstract] [Full Text] [Related]
6. Is visual interpretation of coronary epicardial flow reliable in patients with ST-elevation myocardial infarction undergoing primary angioplasty? Insights from the angiographic substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.
Alhadramy O; Westerhout CM; Brener SJ; Granger CB; Armstrong PW;
Am Heart J; 2010 May; 159(5):899-904. PubMed ID: 20435202
[TBL] [Abstract][Full Text] [Related]
7. Relationship between myocardial reperfusion, infarct size, and mortality: the INFUSE-AMI (Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction) trial.
Brener SJ; Maehara A; Dizon JM; Fahy M; Witzenbichler B; Parise H; El-Omar M; Dambrink JH; Mehran R; Oldroyd K; Gibson CM; Stone GW
JACC Cardiovasc Interv; 2013 Jul; 6(7):718-24. PubMed ID: 23866184
[TBL] [Abstract][Full Text] [Related]
8. Prior coronary artery bypass graft patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
Welsh RC; Granger CB; Westerhout CM; Blankenship JC; Holmes DR; O'Neill WW; Hamm CW; Van de Werf F; Armstrong PW;
JACC Cardiovasc Interv; 2010 Mar; 3(3):343-51. PubMed ID: 20298996
[TBL] [Abstract][Full Text] [Related]
9. Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI angiographic study.
Brener SJ; Moliterno DJ; Aylward PE; van't Hof AW; Ruźyllo W; O'Neill WW; Hamm CW; Westerhout CM; Granger CB; Armstrong PW;
Eur Heart J; 2008 May; 29(9):1127-35. PubMed ID: 18375399
[TBL] [Abstract][Full Text] [Related]
10. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial.
Granger CB; Mahaffey KW; Weaver WD; Theroux P; Hochman JS; Filloon TG; Rollins S; Todaro TG; Nicolau JC; Ruzyllo W; Armstrong PW;
Circulation; 2003 Sep; 108(10):1184-90. PubMed ID: 12925454
[TBL] [Abstract][Full Text] [Related]
11. Utility of cardiac biomarkers in predicting infarct size, left ventricular function, and clinical outcome after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Chia S; Senatore F; Raffel OC; Lee H; Wackers FJ; Jang IK
JACC Cardiovasc Interv; 2008 Aug; 1(4):415-23. PubMed ID: 19463339
[TBL] [Abstract][Full Text] [Related]
12. Extent of RV dysfunction and myocardial infarction assessed by CMR are independent outcome predictors early after STEMI treated with primary angioplasty.
Miszalski-Jamka T; Klimeczek P; Tomala M; Krupiński M; Zawadowski G; Noelting J; Lada M; Sip K; Banyś R; Mazur W; Kereiakes DJ; Zmudka K; Pasowicz M
JACC Cardiovasc Imaging; 2010 Dec; 3(12):1237-46. PubMed ID: 21163452
[TBL] [Abstract][Full Text] [Related]
13. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial.
; Armstrong PW; Granger CB; Adams PX; Hamm C; Holmes D; O'Neill WW; Todaro TG; Vahanian A; Van de Werf F
JAMA; 2007 Jan; 297(1):43-51. PubMed ID: 17200474
[TBL] [Abstract][Full Text] [Related]
14. Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) trial.
Mehta RH; Kaul P; Lopes RD; Patel MR; Zheng Y; Pieper KS; Welsh RC; Armstrong PW; Granger CB
Am Heart J; 2012 May; 163(5):797-803. PubMed ID: 22607857
[TBL] [Abstract][Full Text] [Related]
15. Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.
Martel C; Granger CB; Ghitescu M; Stebbins A; Fortier A; Armstrong PW; Bonnefoy A; Theroux P
Am Heart J; 2012 Jul; 164(1):43-51. PubMed ID: 22795281
[TBL] [Abstract][Full Text] [Related]
16. Early statin treatment prior to primary PCI for acute myocardial infarction: REPERATOR, a randomized placebo-controlled pilot trial.
Post S; Post MC; van den Branden BJ; Eefting FD; Goumans MJ; Stella PR; van Es HW; Wildbergh TX; Rensing BJ; Doevendans PA
Catheter Cardiovasc Interv; 2012 Nov; 80(5):756-65. PubMed ID: 22419603
[TBL] [Abstract][Full Text] [Related]
17. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention.
Bellandi F; Maioli M; Gallopin M; Toso A; Dabizzi RP
Catheter Cardiovasc Interv; 2004 Jun; 62(2):186-92. PubMed ID: 15170708
[TBL] [Abstract][Full Text] [Related]
18. Determinants of myocardial salvage during acute myocardial infarction: evaluation with a combined angiographic and CMR myocardial salvage index.
Ortiz-Pérez JT; Lee DC; Meyers SN; Davidson CJ; Bonow RO; Wu E
JACC Cardiovasc Imaging; 2010 May; 3(5):491-500. PubMed ID: 20466344
[TBL] [Abstract][Full Text] [Related]
19. Early electrocardiographic findings and MR imaging-verified microvascular injury and myocardial infarct size.
Nijveldt R; van der Vleuten PA; Hirsch A; Beek AM; Tio RA; Tijssen JG; Piek JJ; van Rossum AC; Zijlstra F
JACC Cardiovasc Imaging; 2009 Oct; 2(10):1187-94. PubMed ID: 19833308
[TBL] [Abstract][Full Text] [Related]
20. Remote ischemic post-conditioning of the lower limb during primary percutaneous coronary intervention safely reduces enzymatic infarct size in anterior myocardial infarction: a randomized controlled trial.
Crimi G; Pica S; Raineri C; Bramucci E; De Ferrari GM; Klersy C; Ferlini M; Marinoni B; Repetto A; Romeo M; Rosti V; Massa M; Raisaro A; Leonardi S; Rubartelli P; Oltrona Visconti L; Ferrario M
JACC Cardiovasc Interv; 2013 Oct; 6(10):1055-63. PubMed ID: 24156966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
